Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL PACLITAXEL INJECTION MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL PACLITAXEL INJECTION SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL PACLITAXEL INJECTION MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES MODEL
5 INDUSTRY INSIGHTS
5.1 PATENT ANALYSIS
5.1.1 PATENT LANDSCAPE
5.1.2 USPTO NUMBER
5.1.3 PATENT EXPIRY
5.1.4 EPIO NUMBER
5.1.5 PATENT STRENGTH AND QUALITY
5.1.6 PATENT CLAIMS
5.1.7 PATENT CITATIONS
5.1.8 PATENT LITIGATION AND LICENSING
5.1.9 FILE OF PATENT
5.1.10 PATENT RECEIVED CONTRIES
5.1.11 TECHNOLOGY BACKGROUND
5.2 DRUG TREATMENT RATE BY MATURED MARKETS
5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
5.4 PATIENT FLOW DIAGRAM
5.5 KEY PRICING STRATEGIES
5.6 KEY PATIENT ENROLLMENT STRATEGIES
5.7 INTERVIEWS WITH SPECIALIST
5.8 OTHER KOL SNAPSHOTS
6 EPIDEMIOLOGY
6.1 INCIDENCE OF ALL BY GENDER
6.2 TREATMENT RATE
6.3 MORTALITY RATE
6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
6.5 PATIENT TREATMENT SUCCESS RATES
7 MERGERS AND ACQUISITION
7.1 LICENSING
7.2 COMMERCIALIZATION AGREEMENTS
8 REGULATORY FRAMEWORK
8.1 REGULATORY APPROVAL PROCESS
8.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
8.3 REGULATORY APPROVAL PATHWAYS
8.4 LICENSING AND REGISTRATION
8.5 POST-MARKETING SURVEILLANCE
8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE II CANDIDATES
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR PACLITAXEL INJECTION
Company Name Therapeutic Area
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved But Not Yet Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE
Technology Preclinical/ Research Project
PACLITAXEL INJECTION XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR PACLITAXEL INJECTION
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
10 MARKETED DRUG ANALYSIS
10.1 DRUG
10.1.1 BRAND NAME
10.2 THERAPEUTIC INDIACTION
10.3 PHARACOLOGICAL CLASS OD THE DRUG
10.4 DRUG PRIMARY INDICATION
10.5 MARKET STATUS
10.6 DRUG DOSAGES FORM
10.7 DOSAGES AVAILABILITY
10.8 PACKAGING TYPE
10.9 DRUG ROUTE OF ADMINISTRATION
10.1 DOSING FREQUENCY
10.11 DRUG INSIGHT
10.12 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
10.12.1 FORECAST MARKET OUTLOOK
10.12.2 CROSS COMPETITION
10.12.3 THERAPEUTIC PORTFOLIO
10.12.4 CURRENT DEVELOPMENT SCENARIO
11 MARKET ACCESS
11.1 10-YEAR MARKET FORECAST
11.2 CLINICAL TRIAL RECENT UPDATES
11.3 ANNUAL NEW FDA APPROVED DRUGS
11.4 DRUGS MANUFACTURER AND DEALS
11.5 MAJOR DRUG UPTAKE
11.6 CURRENT TREATMENT PRACTICES
11.7 IMPACT OF UPCOMING THERAPY
12 R & D ANALYSIS
12.1 COMPARATIVE ANALYSIS
12.2 DRUG DEVELOPMENTAL LANDSCAPE
12.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
12.4 THERAPEUTIC ASSESSMENT
12.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
13 MARKET OVERVIEW
13.1 DRIVERS
13.2 RESTRAINTS
13.3 OPPORTUNITIES
13.4 CHALLENGES
14 GLOBAL PACLITAXEL INJECTION MARKET, BY TYPE
14.1 OVERVIEW
14.2 GENERIC PACLITAXEL INJECTION
14.2.1 BY DRUG STRENGTH
14.2.1.1. 10MG/ML
14.2.1.2. 20MG/ML
14.2.1.3. 30MG/ML
14.3 BRANDED PACLITAXEL INJECTION
14.3.1 ABRAXANE
14.3.1.1. BY DRUG STRENGTH
14.3.1.1.1. 10MG/ML
14.3.1.1.2. 20MG/ML
14.3.1.1.3. 30MG/ML
14.3.2 TAXOL
14.3.2.1. BY DRUG STRENGTH
14.3.2.1.1. 10MG/ML
14.3.2.1.2. 20MG/ML
14.3.2.1.3. 30MG/ML
14.3.3 CYTAX
14.3.3.1. BY DRUG STRENGTH
14.3.3.1.1. 10MG/ML
14.3.3.1.2. 20MG/ML
14.3.3.1.3. 30MG/ML
14.3.4 ONXOL
14.3.4.1. BY DRUG STRENGTH
14.3.4.1.1. 10MG/ML
14.3.4.1.2. 20MG/ML
14.3.4.1.3. 30MG/ML
14.3.5 OTHERS
15 GLOBAL PACLITAXEL INJECTION MARKET, BY DRUG STRENGTH
15.1 OVERVIEW
15.2 10MG/ML
15.3 20MG/ML
15.4 30MG/ML
16 GLOBAL PACLITAXEL INJECTION MARKET, BY INDICATION
16.1 OVERVIEW
16.2 BREAST CANCER
16.2.1 BY TYPE
16.2.1.1. GENERIC PACLITAXEL INJECTION
16.2.1.2. BRANDED PACLITAXEL INJECTION
16.2.2 BY DRUG STRENGTH
16.2.2.1. 10MG/ML
16.2.2.2. 20MG/ML
16.2.2.3. 30MG/ML
16.3 CERVICAL CANCER
16.3.1 BY TYPE
16.3.2 GENERIC PACLITAXEL INJECTION
16.3.3 BRANDED PACLITAXEL INJECTION
16.3.4 BY DRUG STRENGTH
16.3.5 10MG/ML
16.3.6 20MG/ML
16.3.7 30MG/ML
16.4 OVARIAN CANCER
16.4.1 BY TYPE
16.4.1.1. GENERIC PACLITAXEL INJECTION
16.4.1.2. BRANDED PACLITAXEL INJECTION
16.4.2 BY DRUG STRENGTH
16.4.2.1. 10MG/ML
16.4.2.2. 20MG/ML
16.4.2.3. 30MG/ML
16.5 STOMACH CANCER
16.5.1 BY TYPE
16.5.1.1. GENERIC PACLITAXEL INJECTION
16.5.1.2. BRANDED PACLITAXEL INJECTION
16.5.2 BY DRUG STRENGTH
16.5.2.1. 10MG/ML
16.5.2.2. 20MG/ML
16.5.2.3. 30MG/ML
16.6 PROSTATE CANCER
16.6.1 BY TYPE
16.6.1.1. GENERIC PACLITAXEL INJECTION
16.6.1.2. BRANDED PACLITAXEL INJECTION
16.6.2 BY DRUG STRENGTH
16.6.2.1. 10MG/ML
16.6.2.2. 20MG/ML
16.6.2.3. 30MG/ML
16.7 LUNGS CANCER
16.7.1 BY TYPE
16.7.1.1. GENERIC PACLITAXEL INJECTION
16.7.1.2. BRANDED PACLITAXEL INJECTION
16.7.2 BY DRUG STRENGTH
16.7.2.1. 10MG/ML
16.7.2.2. 20MG/ML
16.7.2.3. 30MG/ML
16.8 TESTICULAR CANCER
16.8.1 BY TYPE
16.8.1.1. GENERIC PACLITAXEL INJECTION
16.8.1.2. BRANDED PACLITAXEL INJECTION
16.8.2 BY DRUG STRENGTH
16.8.2.1. 10MG/ML
16.8.2.2. 20MG/ML
16.8.2.3. 30MG/ML
16.9 PANCREATIC CANCER
16.9.1 BY TYPE
16.9.1.1. GENERIC PACLITAXEL INJECTION
16.9.1.2. BRANDED PACLITAXEL INJECTION
16.9.2 BY DRUG STRENGTH
16.9.2.1. 10MG/ML
16.9.2.2. 20MG/ML
16.9.2.3. 30MG/ML
16.1 OTHERS
17 GLOBAL PACLITAXEL INJECTION MARKET, BY AGE GROUP
17.1 OVERVIEW
17.2 ADULTS
17.3 PEDIATRICS
18 GLOBAL PACLITAXEL INJECTION MARKET, BY GENDER
18.1 OVERVIEW
18.2 MALE
18.3 FEMALE
19 GLOBAL PACLITAXEL INJECTION MARKET, BY END USER
19.1 OVERVIEW
19.2 HOSPITALS
19.3 SPECIALTY CLINICS
19.4 CANCER RESEARCH INSTITUTE
19.5 OTHERS
20 GLOBAL PACLITAXEL INJECTION MARKET, BY DISTRIBUTION CHANNEL
20.1 OVERVIEW
20.2 DIRECT TENDER
20.3 RETAIL SALES
20.3.1 HOSPITAL PHARMACIES
20.3.2 RETAIL PHARMACIES
20.3.3 ONLINE PHARMACIES
20.4 OTHERS
21 GLOBAL PACLITAXEL INJECTION MARKET, SWOT AND DBMR ANALYSIS
22 GLOBAL PACLITAXEL INJECTION MARKET, COMPANY LANDSCAPE
22.1 COMPANY SHARE ANALYSIS: GLOBAL
22.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
22.3 COMPANY SHARE ANALYSIS: EUROPE
22.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
22.5 MERGERS & ACQUISITIONS
22.6 NEW PRODUCT DEVELOPMENT & APPROVALS
22.7 EXPANSIONS
22.8 REGULATORY CHANGES
22.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
23 GLOBAL PACLITAXEL INJECTION MARKET, BY REGION
Global PACLITAXEL INJECTION Market, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
23.1 NORTH AMERICA
23.1.1 U.S.
23.1.2 CANADA
23.1.3 MEXICO
23.2 EUROPE
23.2.1 GERMANY
23.2.2 U.K.
23.2.3 ITALY
23.2.4 FRANCE
23.2.5 SPAIN
23.2.6 RUSSIA
23.2.7 SWITZERLAND
23.2.8 TURKEY
23.2.9 BELGIUM
23.2.10 NETHERLANDS
23.2.11 DENMARK
23.2.12 SWEDEN
23.2.13 POLAND
23.2.14 NORWAY
23.2.15 FINLAND
23.2.16 REST OF EUROPE
23.3 ASIA-PACIFIC
23.3.1 JAPAN
23.3.2 CHINA
23.3.3 SOUTH KOREA
23.3.4 INDIA
23.3.5 SINGAPORE
23.3.6 THAILAND
23.3.7 INDONESIA
23.3.8 MALAYSIA
23.3.9 PHILIPPINES
23.3.10 AUSTRALIA
23.3.11 NEW ZEALAND
23.3.12 VIETNAM
23.3.13 TAIWAN
23.3.14 REST OF ASIA-PACIFIC
23.4 SOUTH AMERICA
23.4.1 BRAZIL
23.4.2 ARGENTINA
23.4.3 REST OF SOUTH AMERICA
23.5 MIDDLE EAST AND AFRICA
23.5.1 SOUTH AFRICA
23.5.2 EGYPT
23.5.3 BAHRAIN
23.5.4 UNITED ARAB EMIRATES
23.5.5 KUWAIT
23.5.6 OMAN
23.5.7 QATAR
23.5.8 SAUDI ARABIA
23.5.9 REST OF MEA
23.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
24 GLOBAL PACLITAXEL INJECTION MARKET, COMPANY PROFILE
24.1 ACCORD HEALTHCARE
24.1.1 COMPANY OVERVIEW
24.1.2 REVENUE ANALYSIS
24.1.3 GEOGRAPHIC PRESENCE
24.1.4 PRODUCT PORTFOLIO
24.1.5 RECENT DEVELOPMENTS
24.2 ALEMBIC PHARMACEUTICALS LIMITED.
24.2.1 COMPANY OVERVIEW
24.2.2 REVENUE ANALYSIS
24.2.3 GEOGRAPHIC PRESENCE
24.2.4 PRODUCT PORTFOLIO
24.2.5 RECENT DEVELOPMENTS
24.3 SALVAVIDAS PHARMACEUTICAL PVT. LTD.
24.3.1 COMPANY OVERVIEW
24.3.2 REVENUE ANALYSIS
24.3.3 GEOGRAPHIC PRESENCE
24.3.4 PRODUCT PORTFOLIO
24.3.5 RECENT DEVELOPMENTS
24.4 TAJ PHARMA INDIA
24.4.1 COMPANY OVERVIEW
24.4.2 REVENUE ANALYSIS
24.4.3 GEOGRAPHIC PRESENCE
24.4.4 PRODUCT PORTFOLIO
24.4.5 RECENT DEVELOPMENTS
24.5 PFIZER
24.5.1 COMPANY OVERVIEW
24.5.2 REVENUE ANALYSIS
24.5.3 GEOGRAPHIC PRESENCE
24.5.4 PRODUCT PORTFOLIO
24.5.5 RECENT DEVELOPMENTS
24.6 ZYDUS GROUP
24.6.1 COMPANY OVERVIEW
24.6.2 REVENUE ANALYSIS
24.6.3 GEOGRAPHIC PRESENCE
24.6.4 PRODUCT PORTFOLIO
24.6.5 RECENT DEVELOPMENTS
24.7 FRESENIUS KABI (SINGAPORE) PTE LTD
24.7.1 COMPANY OVERVIEW
24.7.2 REVENUE ANALYSIS
24.7.3 GEOGRAPHIC PRESENCE
24.7.4 PRODUCT PORTFOLIO
24.7.5 RECENT DEVELOPMENTS
24.8 PANACEA BIOTEC
24.8.1 COMPANY OVERVIEW
24.8.2 REVENUE ANALYSIS
24.8.3 GEOGRAPHIC PRESENCE
24.8.4 PRODUCT PORTFOLIO
24.8.5 RECENT DEVELOPMENTS
24.9 APOTEX INC.
24.9.1 COMPANY OVERVIEW
24.9.2 REVENUE ANALYSIS
24.9.3 GEOGRAPHIC PRESENCE
24.9.4 PRODUCT PORTFOLIO
24.9.5 RECENT DEVELOPMENTS
24.1 TEVA UK LIMITED
24.10.1 COMPANY OVERVIEW
24.10.2 REVENUE ANALYSIS
24.10.3 GEOGRAPHIC PRESENCE
24.10.4 PRODUCT PORTFOLIO
24.10.5 RECENT DEVELOPMENTS
24.11 DR. REDDY’S LABORATORIES LTD.
24.11.1 COMPANY OVERVIEW
24.11.2 REVENUE ANALYSIS
24.11.3 GEOGRAPHIC PRESENCE
24.11.4 PRODUCT PORTFOLIO
24.11.5 RECENT DEVELOPMENTS
24.12 GETWELL PHARMACEUTICALS
24.12.1 COMPANY OVERVIEW
24.12.2 REVENUE ANALYSIS
24.12.3 GEOGRAPHIC PRESENCE
24.12.4 PRODUCT PORTFOLIO
24.12.5 RECENT DEVELOPMENTS
24.13 INTELICURE LIFESCIENCES.
24.13.1 COMPANY OVERVIEW
24.13.2 REVENUE ANALYSIS
24.13.3 GEOGRAPHIC PRESENCE
24.13.4 PRODUCT PORTFOLIO
24.13.5 RECENT DEVELOPMENTS
24.14 BRISTOL-MYERS SQUIBB COMPANY.
24.14.1 COMPANY OVERVIEW
24.14.2 REVENUE ANALYSIS
24.14.3 GEOGRAPHIC PRESENCE
24.14.4 PRODUCT PORTFOLIO
24.14.5 RECENT DEVELOPMENTS
24.15 TWI PHARMACEUTICALS USA, INC.
24.15.1 COMPANY OVERVIEW
24.15.2 REVENUE ANALYSIS
24.15.3 GEOGRAPHIC PRESENCE
24.15.4 PRODUCT PORTFOLIO
24.15.5 RECENT DEVELOPMENTS
24.16 HETERO HEALTHCARE LIMITED
24.16.1 COMPANY OVERVIEW
24.16.2 REVENUE ANALYSIS
24.16.3 GEOGRAPHIC PRESENCE
24.16.4 PRODUCT PORTFOLIO
24.16.5 RECENT DEVELOPMENTS
24.17 ADVACARE PHARMA
24.17.1 COMPANY OVERVIEW
24.17.2 REVENUE ANALYSIS
24.17.3 GEOGRAPHIC PRESENCE
24.17.4 PRODUCT PORTFOLIO
24.17.5 RECENT DEVELOPMENTS
24.18 NOVARTIS AG
24.18.1 COMPANY OVERVIEW
24.18.2 REVENUE ANALYSIS
24.18.3 GEOGRAPHIC PRESENCE
24.18.4 PRODUCT PORTFOLIO
24.18.5 RECENT DEVELOPMENTS
24.19 LEXICARE PHARMA PVT. LTD.
24.19.1 COMPANY OVERVIEW
24.19.2 REVENUE ANALYSIS
24.19.3 GEOGRAPHIC PRESENCE
24.19.4 PRODUCT PORTFOLIO
24.19.5 RECENT DEVELOPMENTS
24.2 BIOZENTA LIFESCIENCES PVT. LTD.
24.20.1 COMPANY OVERVIEW
24.20.2 REVENUE ANALYSIS
24.20.3 GEOGRAPHIC PRESENCE
24.20.4 PRODUCT PORTFOLIO
24.20.5 RECENT DEVELOPMENTS
24.21 CIPLA INC
24.21.1 COMPANY OVERVIEW
24.21.2 REVENUE ANALYSIS
24.21.3 GEOGRAPHIC PRESENCE
24.21.4 PRODUCT PORTFOLIO
24.21.5 RECENT DEVELOPMENTS
24.22 VIATRIS INC.
24.22.1 COMPANY OVERVIEW
24.22.2 REVENUE ANALYSIS
24.22.3 GEOGRAPHIC PRESENCE
24.22.4 PRODUCT PORTFOLIO
24.22.5 RECENT DEVELOPMENTS
24.23 OCEAN PHARMACEUTICAL
24.23.1 COMPANY OVERVIEW
24.23.2 REVENUE ANALYSIS
24.23.3 GEOGRAPHIC PRESENCE
24.23.4 PRODUCT PORTFOLIO
24.23.5 RECENT DEVELOPMENTS
24.24 AETOS PHARMA PRIVATE LIMITED.
24.24.1 COMPANY OVERVIEW
24.24.2 REVENUE ANALYSIS
24.24.3 GEOGRAPHIC PRESENCE
24.24.4 PRODUCT PORTFOLIO
24.24.5 RECENT DEVELOPMENTS
24.25 PV PHARMA
24.25.1 COMPANY OVERVIEW
24.25.2 REVENUE ANALYSIS
24.25.3 GEOGRAPHIC PRESENCE
24.25.4 PRODUCT PORTFOLIO
24.25.5 RECENT DEVELOPMENTS
24.26 ACTIZA PHARMACEUTICAL PRIVATE LIMITED
24.26.1 COMPANY OVERVIEW
24.26.2 REVENUE ANALYSIS
24.26.3 GEOGRAPHIC PRESENCE
24.26.4 PRODUCT PORTFOLIO
24.26.5 RECENT DEVELOPMENTS
24.27 SUNDENT PHARM GROUP
24.27.1 COMPANY OVERVIEW
24.27.2 REVENUE ANALYSIS
24.27.3 GEOGRAPHIC PRESENCE
24.27.4 PRODUCT PORTFOLIO
24.27.5 RECENT DEVELOPMENTS
24.28 NANODARU.
24.28.1 COMPANY OVERVIEW
24.28.2 REVENUE ANALYSIS
24.28.3 GEOGRAPHIC PRESENCE
24.28.4 PRODUCT PORTFOLIO
24.28.5 RECENT DEVELOPMENTS
24.29 HAINAN YEW GARDEN PHARMACEUTICAL CO., LTD
24.29.1 COMPANY OVERVIEW
24.29.2 REVENUE ANALYSIS
24.29.3 GEOGRAPHIC PRESENCE
24.29.4 PRODUCT PORTFOLIO
24.29.5 RECENT DEVELOPMENTS
24.3 STERIMAX
24.30.1 COMPANY OVERVIEW
24.30.2 REVENUE ANALYSIS
24.30.3 GEOGRAPHIC PRESENCE
24.30.4 PRODUCT PORTFOLIO
24.30.5 RECENT DEVELOPMENTS
24.30.6
25 RELATED REPORTS
26 CONCLUSION
27 QUESTIONNAIRE
28 ABOUT DATA BRIDGE MARKET RESEARCH
